Verastem, Inc. (NASDAQ:VSTM)
Historical Stock Chart
2 Months : From Apr 2019 to Jun 2019
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused
on developing and commercializing medicines seeking to improve the
survival and quality of life of cancer patients, today announced that
the Company will present at the 20th Annual B. Riley FBR
Institutional Investor Conference on Thursday, May 23, 2019 at 1:30 p.m.
PDT in Beverly Hills, CA.
A live webcast of the presentation will be available on the investors
section of the Company’s website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem Oncology
Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005067/en/
Verastem Oncology:John DoyleVice President, Investor
Relations & Finance+1 email@example.comInvestors:Joseph
RayneArgot Partners+1 firstname.lastname@example.org